FluoGuide Investor Relations Material
Latest events
Q1 2025
Q4 2024
Latest reports from FluoGuide
FluoGuide is a Danish clinical-stage biotech company specializing in the development of products used to improve cancer surgery. FluoGuide's main product, FG001, is designed to illuminate brain cancer cells during surgery, enabling surgeons to distinguish them more easily from healthy tissue. FG001 is designed to bind specifically to cancer cells, making them visible under a special light during surgery. This aims to reduce the risk of leaving cancerous tissue behind, potentially increasing the success rate of surgeries. The company is also actively researching whether its fluorescent technology can be employed to potentially improve surgery outcomes for a variety of different cancers. FluoGuide is headquartered in Copenhagen, and its shares are listed on Nasdaq Stockholm.
Latest articles
)
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
)
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
)